Clinical Trials

Introduction

  • Conducting clinical trials requires adherence to standardized procedures to ensure:
    • Participant safety.
    • Data integrity.
    • Compliance with ethical guidelines.
  • Key is following the good clinical practice (GCP) framework.
    • Outlines roles and responsibilities for:
      • Investigators
      • Sponsors
      • Institutional review boards (IRBs).
  • Trials begin with protocol development.
    • Detailing study design, objectives, and methodologies.
  • Participant recruitment follows.
    • Informed consent is a crucial step to ensure ethical participation.
  • Regular monitoring and data collection are essential to:
    • Maintain study integrity.
    • Assess treatment efficacy and safety.
  • Trials must also adhere to local and international regulations.
    • Including approvals from regulatory agencies such as:
      • US Food and Drug Administration (FDA).
      • European Medicines Agency (EMA).
  • Data analysis leads to conclusions about the treatment's effectiveness, paving the way for potential market approval.
  • Successful trials require:
    • Coordination
    • Clear communication
    • Commitment to ethical standards, ensuring high-quality results across global populations.

Premarket Studies

  • Premarket phase feasibility/pilot studies:
    • Primary goal: Assess a device's safety and how well it works on a small scale.
    • May evaluate the design, protocols, and safety before moving on to a larger feasibility study.
  • Overall:
    • Test a new device or a novel application of an existing device in a small group of patients to evaluate its initial clinical performance and safety.
  • Premarket phase pivotal study:
    • Conducted to collect more extensive safety and effectiveness data.
    • Typically involve a larger patient group, providing a more comprehensive assessment and most data supporting regulatory approvals.
    • Often, these studies are conducted as Randomized Controlled Trials.
      • Participants are randomly assigned to either the experimental group receiving the device or to a control group.
      • This process is the gold standard for testing the efficacy of an intervention.
  • Manufacturers may also complete Observational Studies.
    • In this case, data are collected on device usage and outcomes without assigning any specific protocol other than standard of care.

Postmarket Studies

  • After a device receives market clearance or approval and has been used in the general population, manufacturers may be required to conduct postmarket surveillance studies to monitor the long-term performance and track adverse events.
  • Patient registry studies:
    • Data are collected on how a device is used and how it performs in a larger population over an extended period of time.
    • May be employed to expand on claims of an already-approved device.

Global Clinical Trial Conduct

  • Largely follow a set of common principles aimed at ensuring the scientific integrity, ethical conduct, and reliability of data.
  • Different countries and regions may have specific regulations and guidelines to accommodate local legal, ethical, and cultural requirements.
  • The operations of clinical trials in most countries are based on several key benchmark regulations and guidelines.

Good Clinical Practice

The Importance of GCP in Clinical Trial Conduct
  • Good clinical practice guidelines are the basis for clinical trials' ethical and scientific conduct.
    • Ensuring the clinical research process's integrity, quality, and safety.
  • These guidelines establish a framework for:
    • Designing
    • Conducting
    • Monitoring
    • Reporting clinical trials.
  • The critical elements of GCP include the following:
Ethical Conduct
  • GCP guidelines emphasize the ethical treatment of human subjects participating in clinical trials.
  • This emphasis can be traced to historical events wherein human rights were not considered in medical research, most notably during the aftermath of World War II.
    • Brought to light egregious human rights violations in the form of unethical medical experiments conducted by the Nazis.
  • In response, the Nuremberg Code (1947) established foundational principles for ethical research, emphasizing:
    • Voluntary informed consent.
    • The well-being of research participants.
  • In 1948, the World Medical Association (WMA) voiced concerns about medical ethics worldwide.
    • The conclusion of the Nuremberg Nazi Doctors' Trial in August 1947 led to the need for reform and the establishment of strengthened principles governing both human and patient rights.
    • The WMA, therefore, decided to take responsibility for setting ethical guidelines for the world's physicians.
    • It adopted a Medical Vow for Physicians, and the assembly agreed to name it the Declaration of Geneva.
  • Following the Declaration of Geneva in 1964, the World Medical Association introduced the Declaration of Helsinki to take it a step further.
    • It outlined ethical principles for medical research involving human subjects.
    • This international guideline emphasizes the importance of research ethics, scientific validity, and informed consent.
    • Laying the groundwork for future regulatory frameworks.
    • The Declaration of Helsinki is still an important principle in clinical research today.
Data Integrity, Quality, Reliability, and Credibility
  • The quality, accuracy, reliability, and completeness of data collected during clinical trials are critical for drawing valid conclusions.
  • The use of robust data management practices, well-designed protocols, standardized procedures, and thorough documentation minimizes errors and biases.
    • Ensuring that results accurately represent the medical device's safety and efficacy.
Participant Safety
  • Implementing safety reporting, monitoring adverse events, and conducting risk assessments are important aspects of GCP.
  • These procedures safeguard participants and contribute to assessing the investigational product's benefit-risk ratio.
Regulatory Compliance
  • Compliance with GCP guidelines is a regulatory requirement enforced by multiple health authorities, including:
    • The FDA
    • The European Medicines Agency (EMA).
    • The Medicines and Healthcare products Regulatory Agency (MHRA).
    • The National Medical Products Administration (NMPA) in China.
    • ANVISA (Agência Nacional de Vigilância Sanitária) in Brazil.
    • COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) in Mexico.
    • DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) in Peru, among many others.
  • Sponsors, investigators, and other stakeholders involved in clinical trials adhere to GCP to meet regulatory expectations and facilitate the acceptance of trial data by the aforementioned regulatory agencies.

ISO 14155

  • ISO 14155:2020 Clinical investigation of medical devices for human subjects is an international standard that standardizes GCP principles for clinical investigations of medical devices.
    • It provides a framework for designing, conducting, recording, and reporting clinical investigations involving human subjects.
    • The standard outlines key principles, including:
      • The ethical treatment of participants.
      • The scientific soundness of the investigation
      • The responsibilities of sponsors and investigators.
  • ISO 14155 aligns with GCP by emphasizing the importance of inspections and audits to verify compliance with ethical, scientific, and regulatory requirements.
  • Both GCP inspections and audits per ISO 14155 assess:
    • The quality management system.
    • Trial conduct
    • The protection of participants
    • These processes contribute to the ongoing oversight and continuous improvement of clinical trial practices.

Informed Consent Process

  • A written consent form that includes all necessary elements must be documented and is known as "informed consent."
  • The informed consent process ensures participants voluntarily and knowledgeably agree to participate in a study with clear communication about the study and its implications between investigators and participants.
  • The document must be signed and dated by the participant or their legally authorized representative before any study-related activities commence.
  • Additional considerations apply when informed consent is obtained from vulnerable populations (e.g., minors, individuals with cognitive impairments, or those with limited decision-making capacity).
    • In these cases, legally authorized representatives' consent becomes essential.
  • The informed consent process generally ensures that:
    • Participants are provided with a clear explanation of any experimental interventions, tests, or assessments they will undergo and are informed about the study's overall purpose, objectives, and procedures.
    • Participants understand any foreseeable adverse effects and potential advantages, contributing to their ability to make an informed decision.
      • All potential risks and benefits in the study are transparently communicated.
    • Participants should be assured that their participation is entirely voluntary, and they can withdraw from the study at any time without facing negative consequences.
    • Participants have the right to know how their data will be handled, stored, and shared.
      • Assurance of confidentiality and protection of privacy build trust and encourage open communication between participants and investigators.
    • In some clinical trials, participants might be randomized to different treatment arms or groups.
      • In such cases, explaining the existence of alternative treatments or procedures that participants might consider is crucial.
    • Participants are provided with clear contact information for the research team to reach out with questions and concerns or in case of emergencies.
  • Regulatory agencies, such as the FDA and the Office for Human Research Protections, the EMA, and China's NMPA have established stringent requirements to ensure informed consent's ethical and legal acquisition.

Investigational Review Boards

  • Institutional review boards serve as safeguards for research participants.
    • Comprising diverse members, including scientists, ethicists, and community representatives, IRBs ensure that clinical trials adhere to ethical principles and regulatory guidelines.
  • Their primary functions include:
    • Reviewing
    • Approving
    • Monitoring research involving human subjects to protect participants' rights, safety, and wellbeing.
  • IRBs evaluate and approve the informed consent forms and process.
    • They ensure the clarity, completeness, and comprehensibility of consent forms, including the risks, benefits, and alternative treatments to safeguard that participants can make informed decisions about their involvement in any clinical research.
    • They also approve any promotional materials or recruitment strategies to ensure they are not coercive or misleading to potential participants.
  • The IRB approval process involves a comprehensive review of research protocols and informed consent documents.
    • Researchers submit detailed plans outlining study design, participant recruitment strategies, and safety monitoring procedures.
    • IRBs assess the proposed research's ethical, scientific, and regulatory aspects, approving only when satisfied that the study is scientifically sound and that the risks to participants have been minimized.
    • They also evaluate the potential benefits and determine whether the study is ethically justified.
  • Once the trial is underway, the IRB continues to monitor its progress through regular reports from the investigators.
    • This may include reviews of adverse event reports and any modifications to the study.
    • They also ensure that the rights and well-being of the participants are maintained throughout the trial.
    • They have the authority to suspend a trial if it appears to be causing unexpected harm to participants.
  • The IRB ensures that the study complies with all regulatory requirements, including federal, state, and local laws and institutional policies.
    • In addition, over time, the trial follows the approved protocols, and any deviations are reviewed and permitted only when they do not affect the participant's safety or the data integrity.
    • As part of these responsibilities, they may need to complete specific reporting to regulatory authorities.
  • At the end of the trial, the IRB reviews the final report to ensure that it accurately reflects the study's outcomes.
    • It assesses data quality and integrity to ensure the data has been collected and recorded accurately and aligns with the protocol and that:
      • Any adverse events or unexpected outcomes, risks, or complications were appropriately addressed and managed.

Documentation, Regional Management, and Regulatory Framework

Clinical Investigation Plans or Clinical Protocols
  • The Clinical Investigation Plan (CIP) or Clinical Protocol is a critical document used to direct the clinical trial.
  • It should address all practical aspects s of all clinical study procedures and requirements.
  • The CIP must be carefully composed to answer specific research questions in a scientifically valid and well-controlled manner.
    • Consideration for patient safety and wellbeing should be prioritized during this process.
  • The methodology should be explained in sufficient detail to allow for repeatability.
  • A protocol should describe the following:
    • Study population
    • Any schedule of tests or procedures
    • Length of the study
    • Rationale for the study
    • Potential benefits and risks of any test articles
    • How the study data will be analyzed and reported
  • It should include the critical study parameters, specifications, and requirements (including regulatory requirements).
  • Sources for this information include:
    • Reviews of relevant scientific literature
    • Reviews of prior relevant clinical studies
    • Reviews of similar commercially available product labeling (if available in public domains), surveys of Key Opinion Leaders, potential end users, and/or advisory committees
    • Meetings with regulatory bodies/agencies
    • Required content based on governing regulations
    • Any preliminary risk or human factors assessments prepared during the product development process
Investigator's Brochure
  • An Investigator's Brochure is a document used to communicate with the IRB and investigators.
  • It contains a summary of any clinical and preclinical data on the investigational device(s) relevant to the clinical investigation of the investigational device(s) in human subjects.
  • It contains a synopsis of the CIP, including:
    • The background and rationale for the study.
    • The study's primary and secondary objectives and endpoints.
    • The study design (multicenter, randomized, controlled trial, single arm, etc.).
    • The relevant study population and any study groups.
    • The number of sites and total number of subjects.
    • Inclusion, and exclusion criteria
    • The study procedures.
  • A background section discusses the device's significance and potential impact.
  • Next, a device description section details the device's intended use and explains how it achieves that purpose, often using diagrams as illustrations.
  • The Study Protocol is then presented in a more detailed manner, providing details to expand on the synopsis provided.
  • Data Management and Adverse Event Reporting are also presented in a detailed manner.
  • Benefit-Risk Assessment section is included to detail the risk category of the detail and any perceived risks or benefits to be realized in the clinical study, with risk protection measures and risk-benefit rationales.
  • The Subject Identification, Recruitment, Consent, and Assent processes are described, and any potential costs to the subject or participant payments are also detailed.
Case Report Forms

  • A Case Report Form (CRF) should be created to allow good analysis of data collected within the trial.

  • An electronic CRF (eCRF) is becoming more common and ensures better overall data integrity throughout the clinical trial.

  • When creating the CRF, obtain any applicable regulatory or guidance documents for the trial/product and review for desired endpoints, data collection intervals, and documentation methods.

  • Validated data collection tools should be used whenever possible.

    • Due to copyright laws, permission could be required to use and/or obtain scores from licensed tools.

  • The information in Figure 18-1 should be found within the CRF or eCRF system.

  • The following should be considered when designing the CRF/eCRF:

    • Forced-choice questions (e.g., checkboxes) should be used versus "fill in the blank" questions when the responses are categorical, can be anticipated, and are limited in number.
    • CRFS should be efficiently completed.
    • A category such as N/A should be used when necessary to avoid boxes or lines being left blank.
    • A 24-hour clock should be used to capture time, or AM or PM must be designated.
    • The international date format (dd-mm-yyyy) should be used as a best practice; the required date format should be clearly conveyed.
    • CRFs should be designed to collect data with a flow that reflects the protocol design.
    • Each data point listed should have a purpose,: and all data points needed to achieve clinical study objectives must be included.

North America

Clinical trials for medical devices in the United States (US)
  • Governed by the FDA under the Center for Devices and Radiological Health (CDRH).
  • In the US, the FDA Safety and Innovation Act, signed into law on 9 July 2012, expanded the FDA's authority to collect user fees, known as the Medical Device User Fee Amendments (MDUFA), which was also passed in 2012.
    • MDUFA intends to expedite the approval of medical devices by promoting the FDA's CDRH regulatory submission review and response timeline.
  • Clinical investigations fall under the categories of non-significant risk (NSR) device studies and significant risk (SR) device studies.
  • An NSR device investigation is one that does not meet the definition for a significant risk device study.
    • However, NSR device studies should not be confused with the concept of "minimal risk,” used in the IRB regulations [21CFR§56.110][21 CFR \S56.110] to identify certain studies eligible for expedited review.
  • A SR device investigation is defined [21CFR§812.3(m)][21 CFR \S812.3(m)] as a clinical investigation of a device that presents a potential for serious risk to the health, safety, or welfare of a subject and
    • is intended as an implant, or
    • is used in supporting or sustaining human life; or
    • is of substantial importance in diagnosing, curing, mitigating or treating disease, or otherwise prevents impairment of human health; or
    • otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.
  • In addition, all US-based applicable clinical trials, as defined in 42 CFR Part 11, must be registered on clinicaltrials.gov.
  • The FDA provides a range of guidance documents to assist sponsors and investigators in conducting clinical trials.
    • Although not required, guidance documents provide an important understanding of how the FDA interprets the most current regulatory requirements.
    • For the most current and comprehensive guidance information that affects medical device clinical trials, users should consult the FDA official website.
  • An Investigational Device Exemption (IDE) application to the FDA is required prior to a trial initiation as well as registration of the clinical trial in a publicly accessible database.
    • Required documents include:
      • Clinical Trial Protocol (including the investigational plan).
      • Investigator's Brochure
      • Informed Consent Form
      • IRB/Ethics Committee Approval
      • Labels for the investigational device
      • Clinical agreements between the sponsor and investigators.

Canada

  • Investigational testing of medical devices in human subjects has become a growing area for research and development in Canada since the establishment of the new Medical Devices Regulations in May 1998.
  • The Food and Drugs Act (FDA) sets out the legislative framework under which medical devices are regulated.
  • The Medical Devices Bureau is responsible for administering the requirements within Part 3 of the Medical Devices Regulations that govern the sale and importation of a medical device for investigational testing involving human subjects.
  • Manufacturers and importers are required to submit Investigational Testing Authorization (ITA) applications to Health Canada to sell or import a medical device for the purpose of conducting investigational testing in human subjects.
  • Health Canada will determine whether:
    • The unlicensed device can be used clinically without seriously endangering the life, health, or safety of patients, users, or other persons.
    • The study is not contrary to the best interests of patients.
    • The testing objectives will be achieved.
  • An ITA is not required if:
    • There is no sale of the medical device (per the definition of sale under the Food and Drugs Act).
    • For the conduct of a study using a licensed device according to its licensed indications for use (whether it is manufacturer or clinician sponsored).
    • Licensed medical devices used in clinician-sponsored investigations that are not initiated by the manufacturer, and are not intended to generate data to support a licensing application do not require an ITA.
  • Upon request, or when determined appropriate, Health Canada will publicly release certain information about issued ITAs to provide transparency and improve public access to information on Canadian studies involving medical devices.
    • For ITAs authorized since 14 November 2013 the following information will be released:
      • Protocol title
      • Device name
      • Medical condition
      • Study population
      • Authorization date
      • End date of the study
      • Name of the manufacturer or importer
Regulatory Framework
  • Manufacturers follow the principles of the Declaration of Helsinki and the Tri-Council Policy Statement (2nd Edition): Ethical Conduct for Research Involving Humans, and conform to good clinical practices as set out by ISO 14155 - Clinical investigation of medical devices for human subjects.
  • Conformity with GCP is strongly recommended, and animal studies should be conducted with scientific rigor similar to that of human trials.
  • Research Ethics Boards (REBs) play an important role in the oversight of the conduct of investigational testing, and REB information is required for all clinical trials involving medical devices by Part 3, section 81 of the Regulations.
  • For Class III and IV medical devices, the REB approval letter must be submitted to Health Canada as soon as it becomes available or prior to initiation of the clinical study, whichever is earlier.
  • Manufacturers and importers are encouraged to request a pre-ITA application meeting, particularly for novel Class III and IV devices and combination products.
    • Manufacturers and importers may invite the qualified investigators who will be involved in the proposed investigation in Canada to attend the meeting.
    • Requests for a consultation meeting or pre-ITA application meeting should be submitted in writing by the manufacturer or importer to the Investigational Testing Division of the Medical Devices Bureau at: hc.it-ee.sc@canada.ca.
Eligible Studies
  • Per the Food and Drugs Act, an ITA application is required for all unlicensed Class II, III, and IV medical devices that will be imported and/or sold in Canada for the purpose of investigational testing involving humans.
Documentation
  • All applications must be submitted electronically in accordance with the current format with the appropriate documentation presented in Table 18-2 for the submission of ITA applications specified in the guidance.
  • For Class I devices, there is no requirement to obtain an ITA for the purposes of conducting investigation testing.
    • However, the manufacturer or importer is still required to possess all the records and information detailed in Section 81.
    • Institutional requirements and Research Ethics Board approval apply.

Mexico

  • In Mexico, the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) operates under the Ministry of Health (Secretaría de Salud) and oversees devices and clinical trials.
  • Mexico also has a decentralized registration process for Research Ethics Committees (RECs) operating through the National Bioethics Commission (Comisión Nacional de Bioética [CONBIOÉTICA]).
  • The rules and guidelines governing trials for devices in Mexico are:
    • The General Health Law, which forms the basis of requirements for health-related matters, including trials
    • The Regulations of the General Health Law on Health Research, which explicitly addresses health research involving subjects, including trials for medical devices
    • The Official Mexican Standards (NOMs).
  • COFEPRIS sets regulations through NOMs, such as NOM 012 SSA3, that outline criteria for conducting trials in Mexico, covering aspects like authorization processes, responsibilities of sponsors and researchers, and ethical considerations, as well as NOM 240 SSA1, which lays out requirements for the evaluation of devices and studies conducted to obtain registration or to fulfill postmarketing commitments.
  • For a long time, ethics committees at each healthcare institution were largely self-regulated and based on international best practices, with a lack of coordination between COFEPRIS and CONBIOÉTICA.
  • However, an Ethics Committee Decree was issued in 2012, establishing its structure, objectives, the roles of ethics committee members, and the applicable requirements for their registry with both CONBIOÉTICA and COFEPRIS.
  • Application for authorization of the clinical trial from COFEPRIS declaration is required prior to a trial initiation as well as registration of the clinical trial in a publicly accessible database.
    • Required documents include:
      • Clinical Trial Protocol
      • Investigator's Brochure
      • Informed Consent Form
      • IRB/Ethics Committee Approval
      • Patient recruitment materials.

European Union

  • Across the European Union (EU) and the European Economic Area (EEA) the European Medicines Agency (EMA) safeguards and advances the wellbeing of both humans and animals through the assessment and supervision of pharmaceuticals.
  • The primary duties of the Agency involve approving and overseeing medicines and medical devices in the EU.
    • Pharmaceutical companies seek a sole marketing authorization from it, which is granted by the European Commission.
    • Once approved, this allows them to market the respective medicine across the EU and the EEA.
    • Due to the comprehensive nature of the centralized process, the majority of truly innovative medicines available in Europe receive authorization from the EMA.
  • The Agency executes its duties by facilitating the advancement and accessibility of medicines, assessing requests for marketing authorizations, overseeing the safety of medicines throughout their existence, and furnishing information to healthcare practitioners and patients.
    • Its activities provide advantages to patients, healthcare providers, scholars, pharmaceutical firms, developers of medicines and medical devices, and policymakers in healthcare.
Regulatory Framework
  • Clinical trials for medical devices in the EU are subject to stringent regulations outlined in Regulation (EU) 2017/745 on Medical Devices (MDRs).
    • This regulation establishes a robust framework to ensure the safety, performance, and efficacy of medical devices through clinical investigations.
  • Before initiating a clinical trial, sponsors must obtain IDE approval from competent authorities, particularly for higher-risk devices.
    • A Clinical Trial Application may also be required in some EU countries, detailing trial specifics and investigational product information.
  • Upon completion, a Clinical Investigation Report (CIR) summarizes trial results, including safety and performance data, in compliance with MDR requirements.
  • Compliance with these regulations ensures that medical devices undergo rigorous evaluation, fostering public trust and promoting patient safety in the EU healthcare system.
Documentation
  • The (EU) 2017/745 on Medical Devices regulation sets out the legal framework for medical devices in the EU, including requirements for clinical investigations.
  • It replaced the previous Medical Devices Directive (93/42/EEC) and Active Implantable Medical Devices Directive (90/385/EEC) and includes more stringent requirements for clinical evidence.
  • The regulation involves adherence to specific requirements outlined in various documents.
    • The primary documents needed for conducting clinical trials on medical devices in the EU include as mentioned earlier:
      • Investigator's Brochure
      • Clinical Investigation Plan
      • Informed Consent Form
      • Ethics Committee approval as well as in Figure 18-5.

United Kingdom

  • The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) stands as a cornerstone in the regulation of clinical trials, ensuring the integrity and safety of medical devices and blood components for transfusion in the UK.
  • Established in 2003, the MHRA plays a pivotal role in safeguarding public health through its rigorous evaluation and oversight mechanisms.
  • Its core responsibilities include ensuring that medicines, medical devices, and blood components meet the highest standards of safety, quality, and effectiveness, as well as establishing secure supply chains for these products.
    • The MHRA also advocates for international standardization and harmonization to enhance the effectiveness and safety of biological medicines.
  • Moreover, the Agency facilitates innovation and supports research and development endeavors that contribute to public health advancement.
  • Through collaboration with partners both domestically and internationally, it strives to expedite access to safe medicines and medical devices while safeguarding public health.
Regulatory Framework
  • As the primary regulatory body for medicines and medical devices in the UK, the MHRA is entrusted with the responsibility of assessing clinical trial applications, ensuring compliance with ethical standards, and monitoring postmarket safety.
  • Under the umbrella of the MHRA, the regulatory landscape has witnessed significant developments, including the implementation of regulations specific to medical devices and subsequent amendments.
  • The MHRA's commitment to transparency and efficiency is reflected in its thorough evaluation processes, which encompass all phases of clinical trials for medical devices.
  • In 2021, the UK transitioned from the EU Clinical Trials Directive to align with international standards.
  • The regulatory framework for medical device clinical trials is primarily governed by the Medical Devices Regulations 2002 and other relevant legislation.
  • Compliance with these regulations and guidelines is essential for conducting clinical trials for medical devices in the UK.
    • Adherence to ethical standards, rigorous study design, data integrity, and patient safety are paramount to the success and validity of clinical research in this field.
Documentation
  • According to global standards, prior to the commencement of a clinical trial, a positive assessment from a Research Ethics Committee, and authorization from the MHRA are required.
  • The sponsor of the clinical trial is responsible for submitting an application including the documents in Figure 18-7.
  • Submitting these documents, along with the CIP, the IB, and information consent form and ethical approval as part of the clinical trial application helps demonstrate the safety, quality, and performance of the medical device and facilitates the MHRA's review and approval process.
    • Sponsors must ensure that all required documents are accurate, complete, and compliant with regulatory standards to expedite approval and ensure the successful conduct of the clinical trial.

China

  • In the dynamic field of medical research and device development, the importance of conducting clinical trials for ensuring safety, efficacy, and compliance cannot be overstated, particularly in China.
  • With its burgeoning biotech and medical device industries, China demands a deep understanding of its distinct regulatory framework, overseen by the National Medical Products Administration (NMPA).
  • China's clinical trial guidelines are established by the NMPA to align with both national and global standards.
  • Those who conduct clinical trials in China must be aware of and understand the unique considerations and requirements in this complex regulatory environment.
Regulatory Framework
  • In China, the regulatory oversight for clinical trials falls under the jurisdiction of the NMPA.
  • This oversight is primarily guided by the "Regulations on the Supervision and Administration of Medical Devices," which was promulgated as State Council Order No. 739 in 2021.
    • These regulations stipulate that any clinical trials related to medical devices must strictly follow the good clinical practice guidelines tailored for medical devices, as outlined in Article 26 of the regulations.
  • Moreover, the governance of international collaborative clinical trials, especially those involving human genetic resources, is further detailed in the "Regulations of the People's Republic of China on the Administration of Human Genetic Resources" (State Council Order No. 717, 2019).
    • According to this directive, such trials require either explicit approval or a formal filing with the Ministry of Science and Technology, ensuring a comprehensive regulatory compliance framework that spans both medical device trials and genetic research.
  • This dual-layered regulatory approach underscores China's commitment to maintaining stringent standards for clinical trials, ensuring ethical considerations and participant safety, while fostering international cooperation in medical and genetic research.
  • When navigating the clinical trial landscape in China, it is essential to consider specific regulatory and cultural factors that extend beyond the International Helsinki Declaration's clinical standards.
    • These factors are deeply rooted in China's unique regulatory framework and cultural practices, playing a crucial role in the successful execution of clinical trials, as defined in Figure 18-8.
Documentation
  • For medical device products and in vitro diagnostic (IVD) products, clinical trials must comply with the good clinical practice for Medical Devices.
    • Additionally, they should follow specific technical guidelines and guidance documents that cover various aspects such as clinical evaluation, report writing, trial design, acceptance of foreign data, and data submission requirements for registration review.
    • Each category also has its own set of specific guidelines tailored to the unique needs of medical devices and IVD products, respectively.
Global Considerations
  • The China National Medical Products Administration issued Notice No. 13 of 2018 on 11 January 2018, introducing technical guidance for accepting foreign clinical trial data for medical devices.
    • This initiative aims to implement reforms in the review and approval system, enhance the management of medical device product registration, improve the quality of registration review, and encourage innovation in medical device research and development.
  • The guidance outlines the principles and requirements for incorporating clinical trial data from outside China into the domestic registration process for medical devices.
  • It specifies that such data, generated under normal usage conditions by clinical trial institutions abroad that meet local requirements, should confirm the device's safety and effectiveness.
  • The principles for acceptance stress adherence to ethical and legal standards during trials.
  • Key considerations include ensuring data meets China's technical and regulatory standards, accounting for differences in subject populations, and evaluating trial conditions' comparability to those in China.
  • This initiative aims to streamline the approval process, foster international cooperation, and introduce innovative medical devices to the Chinese market, ensuring their safety and effectiveness for local patients.

Brazil

  • In Brazil, the regulatory authority overseeing medical devices, including clinical trials, is the National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA).
  • The rigorous legal and regulatory framework governing clinical trials for medical devices has been harmonized with international standards to ensure their safety, efficacy, and quality.
  • The regulatory requirements for conducting clinical trials with medical devices in Brazil include Resolution of the Collegiate Board No. 9/2015, which provides specific guidelines for conducting clinical trials with medical devices in Brazil.
    • It includes requirements for trial design, ethical considerations, informed consent, and the need for approval from an accredited ethics committee as well as ANVISA.
  • The Brazilian General Data Protection Law, while not exclusively focused on clinical trials, encompasses the handling of personal data in clinical research.
    • It requires the protection of trial subject data, which impacts how clinical trial data are managed.
  • The National Commission of Ethics in Research (Comissão Nacional de Ética em Pesquisa, CONEP): CONEP is responsible for the ethical review of high-risk clinical trials, which includes certain types of trials involving medical devices.
    • Approval from CONEP is often required in addition to local ethics committee approval.
  • A registration of the clinical trial in a publicly accessible database is required.
    • Additional required documents include:
      • Clinical Trial Protocol
      • Investigator's Brochure
      • Informed Consent Form
      • IRB/Ethics Committee Approval
      • A Clinical trial Agreement between the Sponsor, clinical sites, and investigators and a safety reporting procedures.

Argentina

  • In Argentina, the regulation of clinical trials for medical devices falls under the purview of the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), which is the national administration responsible for medicines, food, and medical technology.
  • The key regulations and guidelines for clinical trials with medical devices in Argentina are:
    • Disposición 6677/2010, which establishes the requirements for the development of clinical investigations with medical devices in Argentina.
      • It includes stipulations for submitting clinical trials, evaluation processes, and essential documentation needed for obtaining approval to start a trial.
    • Law 27.491 on the Research and Development of Medicines and Medical Devices regulates all aspects of the development process, including the need for ethics committee approvals and ANMAT's oversight.
  • Depending on the class of the device, a declaration from ANMAT stating that the trial can be initiated is required prior to a trial initiation as well as registration of the clinical trial in a publicly accessible database.